Intrust Bank NA Has $744,000 Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Intrust Bank NA grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) by 8.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,576 shares of the pharmaceutical company’s stock after buying an additional 205 shares during the period. Intrust Bank NA’s holdings in Vertex Pharmaceuticals were worth $744,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. raised its holdings in Vertex Pharmaceuticals by 0.4% in the 3rd quarter. BlackRock Inc. now owns 25,243,060 shares of the pharmaceutical company’s stock valued at $7,308,875,000 after acquiring an additional 105,908 shares in the last quarter. Vanguard Group Inc. raised its holdings in Vertex Pharmaceuticals by 1.4% in the 3rd quarter. Vanguard Group Inc. now owns 21,132,336 shares of the pharmaceutical company’s stock valued at $6,118,657,000 after acquiring an additional 293,861 shares in the last quarter. State Street Corp raised its holdings in Vertex Pharmaceuticals by 0.3% in the 3rd quarter. State Street Corp now owns 12,294,791 shares of the pharmaceutical company’s stock valued at $3,559,834,000 after acquiring an additional 30,742 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Vertex Pharmaceuticals by 3.9% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 5,157,954 shares of the pharmaceutical company’s stock valued at $1,493,458,000 after acquiring an additional 195,271 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in Vertex Pharmaceuticals by 7.6% in the 4th quarter. Jennison Associates LLC now owns 5,115,540 shares of the pharmaceutical company’s stock valued at $1,477,266,000 after acquiring an additional 359,719 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Down 0.4 %

Shares of NASDAQ:VRTX opened at $332.63 on Friday. The company has a market capitalization of $85.67 billion, a price-to-earnings ratio of 26.48, a P/E/G ratio of 3.12 and a beta of 0.49. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.28 and a quick ratio of 4.11. The business’s 50-day moving average is $328.99 and its 200-day moving average is $311.29. Vertex Pharmaceuticals Incorporated has a 1 year low of $243.17 and a 1 year high of $354.46.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last announced its quarterly earnings data on Monday, May 1st. The pharmaceutical company reported $3.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.54. The company had revenue of $2.37 billion for the quarter, compared to the consensus estimate of $2.34 billion. Vertex Pharmaceuticals had a return on equity of 25.06% and a net margin of 35.40%. The firm’s revenue was up 13.2% compared to the same quarter last year. During the same period in the previous year, the business earned $3.16 EPS. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 13.06 earnings per share for the current year.

Analysts Set New Price Targets

VRTX has been the topic of several recent analyst reports. HC Wainwright lifted their price target on Vertex Pharmaceuticals from $326.00 to $380.00 in a research note on Tuesday, May 2nd. Maxim Group boosted their price objective on Vertex Pharmaceuticals from $325.00 to $400.00 in a research report on Wednesday, May 3rd. StockNews.com started coverage on Vertex Pharmaceuticals in a research report on Thursday, May 18th. They set a “strong-buy” rating on the stock. Robert W. Baird boosted their price objective on Vertex Pharmaceuticals from $280.00 to $325.00 in a research report on Tuesday, May 2nd. Finally, Truist Financial boosted their price objective on Vertex Pharmaceuticals from $341.00 to $456.00 in a research report on Tuesday, May 2nd. Six equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $352.59.

Insider Buying and Selling

In related news, EVP Bastiano Sanna sold 2,850 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $350.00, for a total transaction of $997,500.00. Following the transaction, the executive vice president now directly owns 32,038 shares of the company’s stock, valued at approximately $11,213,300. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, EVP Bastiano Sanna sold 2,850 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $350.00, for a total transaction of $997,500.00. Following the transaction, the executive vice president now directly owns 32,038 shares of the company’s stock, valued at approximately $11,213,300. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $287.48, for a total value of $101,767.92. Following the sale, the executive vice president now directly owns 56,805 shares of the company’s stock, valued at $16,330,301.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 64,497 shares of company stock valued at $20,835,867. 0.40% of the stock is owned by company insiders.

Vertex Pharmaceuticals Profile

(Get Rating)

Vertex Pharmaceuticals, Inc is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.